BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, May 2, 2024
See today's BioWorld
Home
» CRS wants to know: Is Medicaid contributing to high drug prices?
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
CRS wants to know: Is Medicaid contributing to high drug prices?
Nov. 19, 2014
By
Mari Serebrov
No Comments
Ever since Gilead Sciences Inc. unveiled its $84,000 price tag for Solvaldi, a breakthrough hepatitis C drug, many lawmakers, patient groups and payers have been throwing warning flags about the escalating price of drugs.
BioWorld